To direct the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, to take certain steps to increase clinical trial diversity, and for other purposes.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill, To direct the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, to take certain steps to increase clinical trial diversity, and for other purposes., changes federal law or congressional policy affecting health care providers and patients. The main policy domain is Healthcare, Government Operations, Education.
Who Benefits and How
health care providers and patients may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.
Who Bears the Burden and How
federal implementing agencies, health care providers and patients may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.
Key Provisions
- Section HDF16A6CE66104E37905C8DEB3191A081: 1. Short title This Act may be cited as the NIH Clinical Trial Diversity Act of 2023.
- Section idb1cb8a02575b4cd5ae3399897c7434cd: 2. Diversity goals for clinical trials funded by the National Institutes of Health Beginning on the date of enactment of this Act, the Secretary of Health and...
- Section id72de01d46fd64cb6b81aa8695fd9f8ab: 3. Eliminating cost barriers Not later than 2 years after the date of enactment of this Act, the Secretary of Health and Human Services, acting through the...
- Section id9470477429794763b3322258d98ec5a9: 4. Public awareness and education campaign The Secretary of Health and Human Services (referred to in this section as the Secretary), in consultation with the...
- Section id0cd85d72a45d48fa9ebb9c5e71a7b400: 5. Definition In this Act, the term clinical trial means a research study in which one or more human subjects are prospectively assigned to one or more...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
This bill, To direct the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, to take certain steps to increase clinical trial diversity, and for other purposes., changes federal law or congressional policy affecting health care providers and patients.
Key Policy Areas
Healthcare, Government Operations, Education
Primary Purpose
This bill, To direct the Secretary of Health and Human Services, acting through the Director of the National Institutes of Health, to take certain steps to increase clinical trial diversity, and for other purposes., changes federal law or congressional policy affecting health care providers and patients.
Policy Domains
Whole bill
Identified Gains
- health care providers and patients
Identified Costs
- federal implementing agencies
- health care providers and patients
Sponsors
Legislative Progress
IntroducedMr. Menendez (for himself and Ms. Collins) introduced the following …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "secretary_of_health_and_human_services"
- → Secretary of Health and Human Services
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology